Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CLOVIS ONCOLOGY, INC.

(CLVS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/30/2021 08/02/2021 08/03/2021 08/04/2021 08/05/2021 Date
4.83(c) 4.92(c) 4.86(c) 4.82(c) 5.06(c) Last
2 081 921 1 982 004 3 084 733 5 334 053 3 078 336 Volume
-0.41% +1.86% -1.22% -0.82% +4.98% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 159 M - -
Net income 2021 -244 M - -
Net Debt 2021 247 M - -
P/E ratio 2021 -2,28x
Yield 2021 -
Sales 2022 210 M - -
Net income 2022 -161 M - -
Net Debt 2022 236 M - -
P/E ratio 2022 -3,77x
Yield 2022 -
Capitalization 599 M 599 M -
EV / Sales 2021 5,34x
EV / Sales 2022 3,97x
Nbr of Employees 429
Free-Float 98,2%
More Financials
Company
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The CompanyÔÇÖs product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial... 
More about the company
Ratings of Clovis Oncology, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about CLOVIS ONCOLOGY, INC.
06:58aCLOVIS ONCOLOGY : HC Wainwright Adjusts Clovis Oncology's Price Target to $10 Fr..
MT
08/04CLOVIS ONCOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
AQ
08/04CLOVIS ONCOLOGY : Announces Second Quarter 2021 Operating Results (Form 8-K)
PU
08/04CLOVIS : Q2 Earnings Snapshot
AQ
08/04CLOVIS ONCOLOGY, INC. : Results of Operations and Financial Condition, Regulatio..
AQ
08/04CLOVIS ONCOLOGY : Announces Second Quarter 2021 Operating Results
BU
07/21CLOVIS ONCOLOGY : to Announce Second Quarter 2021 Financial Results and Host Web..
BU
07/13CLOVIS ONCOLOGY, INC. : Change in Directors or Principal Officers, Financial Sta..
AQ
07/12CLOVIS ONCOLOGY : Appoints Dr. Ronit Simantov to its Board of Directors
BU
07/12Clovis Oncology Appoints Dr. Ronit Simantov to Its Board of Directors
CI
06/28CLOVIS ONCOLOGY : Initial Clinical Experience of FAP-2286 in Independent Named P..
BU
06/25CLOVIS ONCOLOGY, INC.(NASDAQGS : CLVS) added to Russell 3000E Index
CI
06/25CLOVIS ONCOLOGY, INC.(NASDAQGS : CLVS) added to Russell Microcap Index
CI
06/25CLOVIS ONCOLOGY, INC.(NASDAQGS : CLVS) added to Russell Microcap Growth Index
CI
06/25CLOVIS ONCOLOGY, INC.(NASDAQGS : CLVS) added to Russell 3000E Growth Index
CI
More news
News in other languages on CLOVIS ONCOLOGY, INC.
2019CLOVIS ONCOLOGY : annonce le remboursement des comprimés de « (rucaparib) pour l..
2019CLOVIS ONCOLOGY : kündigt Erstattung für Rubraca«-Tabletten (Rucaparib) für Frau..
2018CLOVIS ONCOLOGY : Le CHMP émet un avis positif concernant la nouvelle indication..
2018CLOVIS ONCOLOGY : CHMP gibt positive Stellungnahme für die neue Indikation der R..
2018WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on CLOVIS ONCOLOGY, INC.
More recommendations
Chart CLOVIS ONCOLOGY, INC.
Duration : Period :
Clovis Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLOVIS ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Last Close Price 5,06 $
Average target price 5,90 $
Spread / Average Target 16,6%
EPS Revisions
Managers and Directors
Patrick J. Mahaffy President, Chief Executive Officer & Director
Daniel W. Muehl Chief Financial Officer & Executive Vice President
Ginger L. Graham Chairman
Lindsey Rolfe Chief Medical Officer & Executive VP-Clinical
Thomas Fuglsang Harding Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
CLOVIS ONCOLOGY, INC.0.42%504
BIONTECH SE408.39%100 096
GILEAD SCIENCES, INC.19.86%86 839
WUXI APPTEC CO., LTD.43.36%72 049
REGENERON PHARMACEUTICALS21.40%60 161
VERTEX PHARMACEUTICALS-15.55%51 779